Tegonat 20mg Capsule

About

Tegafur is an oral fluoropyrimidine antineoplastic agent, functioning as a prodrug that is converted in the body to fluorouracil (5-FU). Fluorouracil works by interfering with DNA and RNA synthesis in rapidly dividing cancer cells, thereby inhibiting their growth and proliferation. This mechanism of action classifies it as an antimetabolite, specifically targeting pyrimidine synthesis. Tegafur is often used in combination regimens, particularly for gastrointestinal cancers, where it provides a convenient oral alternative to intravenous 5-FU. Its systemic conversion to the active drug allows for sustained exposure to the cytotoxic agent, contributing to its therapeutic efficacy in various solid tumors. It plays a crucial role in adjuvant and palliative settings for several malignancies.

Uses

• Treatment of advanced gastric cancer.
• Management of colorectal cancer.
• Treatment of head and neck cancers.
• Used in combination with other chemotherapeutic agents.

Directions For Use

Take the capsules orally with water, as directed by your physician. It may be taken with or without food, but consistency is important. Do not open or crush the capsules.

Benefits

• Effective in treating various solid tumors, especially GI cancers.
• Oral formulation offers convenience and reduces hospital visits.
• Can be part of combination chemotherapy regimens.
• Helps to control tumor growth and progression.
• May improve survival rates in specific cancer types.
• Provides a sustained release of the active cytotoxic agent.

Side Effects

• Nausea and vomiting
• Diarrhea
• Stomatitis (mouth sores)
• Fatigue
• Loss of appetite
• Myelosuppression (low blood counts)
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Abdominal pain
• Skin rash
• Hair thinning
• Taste disturbance
• Dehydration

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may worsen gastrointestinal side effects and potentially increase liver toxicity.
• Pregnancy - Tegafur is teratogenic and contraindicated in pregnancy. Women of childbearing potential must use effective contraception during and for a period after treatment.
• Breastfeeding - Breastfeeding is contraindicated during Tegafur treatment and for a period after, due to the potential for serious adverse effects in the infant.
• Liver - Use with caution in patients with hepatic impairment. Liver function should be monitored regularly, and dose adjustments may be necessary.
• Kidney - Use with caution in patients with renal impairment. Dosage adjustments may be required based on creatinine clearance.
• Lung - Rarely, pulmonary toxicity such as interstitial pneumonia can occur. Patients should report any new or worsening respiratory symptoms promptly.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.